Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $443K fell 98.4% year over year, behind the -97.6% change in trailing-twelve-month cost of revenue.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of -97.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$443K— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$1.39M-97.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.4%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 cost of revenue of $1.39M is the lowest of the 3 companies compared; the peer median is $39.87M.
  • Its year-over-year change of -97.6% is the lowest of 3, against a peer median of -19.7%.
  • Cost of revenue amounts to 0.4% of revenue for IRWD, versus a peer median of 29.0%.
IRWD Competitors Peer median
Cost of Revenue for IRWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$45.25M +0.0%—50.0%
ARDXArdelyx, Inc.LTM Mar 2026$34.5M -39.4%+117.9%8.1%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$1.39M -97.6%—0.4%
Peer median (excluding IRWD) $39.87M-19.7%+117.9%29.0%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue413.75M410.6M442.74M351.41M296.15M
Cost of Revenue70.41M1.42M6.15M7.55M0
Gross Profit343.35M409.18M436.59M343.86M296.15M
Gross Margin83.0%99.7%98.6%97.9%100.0%
Research & Development70.41M44.27M116.09M111.42M95.14M
Selling, General & Admin0115.99M0082.26M
Operating Expenses111.09M158.84M1.38B250.73M177.39M
Depreciation & Amortization1.52M1.42M1.58M2.01M1.88M
EBITDA233.74M261.44M197.41M97.73M104.65M
EBITDA Margin56.5%63.7%44.6%27.8%35.3%
Operating Income232.26M250.34M(945.43M)93.12M118.76M
Operating Margin56.1%61.0%-213.5%26.5%40.1%
Interest Income726K9.5M18.97M4.47M4.08M
Interest Expense31.15M7.6M21.63M33.03M32.75M
Other Income / Expenses(31.6M)2.09M(2.64M)(27.93M)(48.73M)
Income Before Tax200.66M252.42M(948.07M)65.2M70.03M
Pre-Tax Margin48.5%61.5%-214.1%18.6%23.6%
Income Tax Expense(327.79M)77.36M83.49M64.32M46.01M
Net Income528.45M175.07M(1B)880K24.02M
Net Margin127.7%42.6%-226.4%0.3%8.1%
EPS (Basic)3.261.13(6.45)0.010.15
EPS (Diluted)3.210.96(6.45)0.010.15
Weighted Avg Shares162.25M154.37M155.44M159.08M162.22M
Weighted Avg Shares (Diluted)164.42M186.31M155.44M160.08M177.76M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.